TiGenix completes second phase of the Orthomimetics acquisition

Leuven (Belgium) - November 9, 2010 - TiGenix (NYSE Euronext Brussels: TIG) announces that it has completed the second phase of the Orthomimetics acquisition.

TiGenix has performed a capital increase of 1.1 million EUR in exchange for the issuance of 252,486 new TiGenix shares (at an issuance price of EUR 4.28 per new share). The capital increase was performed through the contribution in kind of part of the receivable of former shareholders of Orthomimetics Limited resulting from their sale of 680,686 Orthomimetics shares, valued at 3.4 million EUR, to TiGenix on November 30, 2009 and marks the second phase of the Orthomimetics acquisition. In this regard, TiGenix also refers to its previous press release of December 1, 2009.

The 252,486 new TiGenix shares will be admitted to trading on NYSE Euronext Brussels. Following this transaction, the total number of shares outstanding is 31,121,154. A maximum of 536,534 could be created and admitted to trading in the third and remaining phase of the Orthomimetics acquisition by March 30, 2012.

For more information, please contact:
Gil Beyen
Chief Executive Officer

Frank Hazevoets
Chief Financial Officer

+32 16 39 60 60
Investor@tigenix.com